07:30:22 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-25 Kvartalsrapport 2024-Q3
2024-07-19 Kvartalsrapport 2024-Q2
2024-04-26 Ordinarie utdelning EPRO B 0.80 SEK
2024-04-25 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-02-01 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-07-21 Kvartalsrapport 2023-Q2
2023-04-27 Ordinarie utdelning EPRO B 0.70 SEK
2023-04-26 Årsstämma 2023
2023-04-25 Kvartalsrapport 2023-Q1
2023-01-31 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning EPRO B 0.50 SEK
2022-04-28 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-01-28 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-22 Kvartalsrapport 2021-Q2
2021-04-29 Ordinarie utdelning EPRO B 0.00 SEK
2021-04-28 Årsstämma 2021
2021-04-27 Kvartalsrapport 2021-Q1
2021-02-03 Bokslutskommuniké 2020
2020-10-30 Kvartalsrapport 2020-Q3
2020-07-24 Kvartalsrapport 2020-Q2
2020-05-06 Kvartalsrapport 2020-Q1
2020-04-01 Ordinarie utdelning EPRO B 0.00 SEK
2020-04-01 Ordinarie utdelning EPRO A 0.00 SEK
2020-03-31 Årsstämma 2020

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHandel & varor
IndustriSällanköpsvaror
Electrolux Professional är en global leverantör av professionell utrustning inom storkök, dryck och tvätt. Produktutbudet inkluderar ugnar, kylskåp, diskmaskiner, kaffebryggare, tvättmaskiner, torktumlare samt service och specialprodukter och relaterade tillbehör. Bolagets produkter tillverkas vid flertalet anläggningar runt om i världen. Kunderna återfinns bland restauranger, hotell, hälso- och sjukvård, skolor och andra serviceinrättningar.
2021-04-29 08:00:00

In cooperation with the UK life science company BiologIC Technologies and Astra Zeneca Cambridge COVID-19 Test center, Electrolux Professional's award winning SkyLine combi oven will be used to support a high-throughput solution for heat inactivation of COVID-19 patient samples.

"With the advanced technology of the SkyLine combi oven, we support yet another milestone in fighting the pandemic that is affecting people and businesses around the world. We are very proud to play a role in safeguarding the process of handling the COVID-19 samples, to protect all people involved in testing", says Alberto Zanata, CEO Electrolux Professional.

The solution which uses the SkyLine combi oven increases safety for testing personnel, reduces the costs and waste associated with biocontainment infrastructure, and also opens the opportunity for further automation of the testing process to materially increase diagnostic throughput at a reduced cost. BiologIC, AstraZeneca and Electrolux Professional collaborated to combine bioscience and thermal expertise in order to rapidly innovate and industrialize a production-ready heat inactivation solution in a safety-critical process.

Richard Vellacott, CEO of BiologIC Technologies, comment: "Combined with vaccines, diagnostic testing will be critical to re-mobilising our communities, particularly as new strains of COVID-19 continue to evolve. We look forward to supporting more labs around the world in implementing this solution, using BiologIC's Industry 4.0 life science expertise with the SkyLine oven from Electrolux Professional".

 

SkyLine combi ovens from Electrolux Professional

Smart technology and human-centred design, the SkyLine Combi Ovens are made to deliver outstanding performance, characterized by reduced running costs and designed with the operator in mind in terms of better ergonomics and usability.

BiologIC Technologies

BiologIC's vision is to integrate Industry 4.0 technologies to power a bio revolution that solves enormous challenges faced by humanity (feeding 9.8 billion people by 2050, reversing climate change and mitigating the threat of diseases) in an environmentally sustainable, economically accessible way. Read more: https://www.biologic-tech.com/solutions/virology

AstraZeneca Cambridge COVID-19 test centre

Established by AstraZeneca, the University of Cambridge and GlaxoSmithKline, and subsequently partnering with Charles River Laboratories, is part of the UK Government Lighthouse Laboratory programme for population-wide diagnostic testing.

 

Media contact Jacob Broberg, Senior Vice President Investor Relations and Communications +46 70 190 00 33